Royalty Pharma Acquires Remaining Evrysdi Royalties From PTC Therapeutics

December 29, 2025 — 09:15 pm EST

Written by RTTNews.com for RTTNews

(RTTNews) - Royalty Pharma plc (RPRX) announced that it has acquired the final portion of PTC Therapeutics' remaining royalty interest in Roche's Evrysdi. The transaction includes an upfront payment of $240 million and up to $60 million in sales-based milestone payments.

Following the completion of this deal, Royalty Pharma will own 100% of the tiered royalty paid by Roche on worldwide net sales of Evrysdi. The royalty structure entitles Royalty Pharma to 8% on sales up to $500 million, 11% on sales between $500 million and $1 billion, 14% on sales between $1 billion and $2 billion, and 16% on sales exceeding $2 billion.

Royalty Pharma will begin receiving the increased royalty in the first quarter of 2026, based on Evrysdi product sales recorded in the fourth quarter of 2025.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Royalty Pharma Acquires Remaining Evrysdi Royalties From PTC Therapeutics

Tags

Latest Articles